Profilo
Stephen Dowd worked as a Senior Director of Business Development at Kymab Ltd., a Team Leader at GSK Plc, and a Senior Business Development Manager at Arecor Ltd.
He also served as the Head of Business Development at Rallybio Corp.
from 2021 to 2023.
Dr. Dowd holds an MBA from the University of Cambridge and a doctorate from the University of Dundee.
Precedenti posizioni note di Stephen Dowd
| Società | Posizione | Fine |
|---|---|---|
| RALLYBIO CORPORATION | Corporate Officer/Principal | 01/09/2023 |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
Arecor Ltd.
 Arecor Ltd. BiotechnologyHealth Technology Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Formazione di Stephen Dowd
| University of Cambridge | Masters Business Admin |
| University Of Dundee | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GSK PLC | Health Technology |
| RALLYBIO CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Arecor Ltd.
Arecor Ltd. BiotechnologyHealth Technology Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Stephen Dowd
